As a point of reference, research has shown that, on average, patients who are overweight or living with obesity can lose 10% to 20% of their total body weight on a GLP-1, depending on a few different factors
In concert, these results define a new scenario of action for incretin-based therapy that may involve the adipo-insular axis, linking the weight lowering competence with the sustained protection of -cells from diabetogenic stressors
Daily promotions We run daily offers so you can make the most of our deals
Specifically, the PI3K/AKT pathway has been identified as a critical signaling axis responsible for mediating the effects of IGF-1 in these contexts
These findings highlight the need for context-specific autophagy modulation and indicate that therapeutic success depends on pharmacologic refinement, advanced delivery, and patient stratification
FDA drug shortages [Internet]